Literature DB >> 29544956

Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study.

Tobias Koppara1, Tomohisa Tada2, Erion Xhepa3, Sebastian Kufner3, Robert A Byrne3, Tareq Ibrahim4, Karl-Ludwig Laugwitz5, Adnan Kastrati3, Michael Joner6.   

Abstract

BACKGROUND: Drug-eluting stents with biodegradable polymer coatings have shown promising outcomes in randomised studies.
METHODS: We compared neointimal healing patterns including strut coverage and assessed neointimal maturity using a novel algorithm in coronary lesions treated with sirolimus-eluting stents with biodegradable polymer coating (BP-SES) or everolimus eluting stents with permanent polymer coating (PP-EES) using optical coherence tomography after 6months.
RESULTS: A total of 39 patients were randomised to BP-SES (n=19) or PP-EES (n=20) for the treatment of coronary lesions. Of those, 29 patients (14 BP-SES and 15 PP-EES) underwent optical coherence tomography (OCT) and angiography at 6-month follow-up. Tissue coverage and apposition were assessed in a total of 6162 struts (BP-SES, n=2889; PP-EES, n=3273). Neointimal maturity was assessed in 3672 neointimal regions above struts using grey scale intensity analysis. OCT analysis showed neointimal coverage of 2433 (BP-SES) vs. 2702 (PP-EES) struts (84.2% vs. 82.6%, p=0.70), whereas the remainder was uncovered after 6months. Mean neointimal thickness did not differ significantly between groups (54.3±7.8μm vs. 80±14.6μm, p=0.12). The rate of malapposed struts was comparable between groups (1.3% vs. 2.2%, p=0.27). Grey scale signal intensity analysis showed mature tissue coverage of struts in 46.2% in BP-SES vs. 31.8% in PP-EES (p=0.31) of neointimal regions.
CONCLUSION: The present study showed comparable early vascular healing response characterised by neointimal coverage with mainly immature neointima in both BP-SES and PP-EES.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biodegradable polymer coating; Optical coherence tomography; Percutaneous coronary intervention

Mesh:

Substances:

Year:  2018        PMID: 29544956     DOI: 10.1016/j.ijcard.2018.01.011

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis.

Authors:  Erion Xhepa; Robert A Byrne; Fernando Rivero; Andi Rroku; Javier Cuesta; Gjin Ndrepepa; Sebastian Kufner; Teresa Bastante Valiente; Salvatore Cassese; Marcos Garcia-Guimaraes; Anna Lena Lahmann; Himanshu Rai; Heribert Schunkert; Michael Joner; María José Pérez-Vizcayno; Nieves Gonzalo; Fernando Alfonso; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2019-02-19       Impact factor: 5.460

Review 2.  Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description.

Authors:  Matthias Waliszewski; Mark Rosenberg; Harald Rittger; Viktor Breul; Florian Krackhardt
Journal:  Ther Adv Cardiovasc Dis       Date:  2020 Jan-Dec

3.  Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study.

Authors:  Atul Abhyankar; Alexandre Abizaid; Daniel Chamié; Mihir Rathod
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-03       Impact factor: 2.692

4.  Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial.

Authors:  Himanshu Rai; Fernando Alfonso; Michael Maeng; Christian Bradaric; Jens Wiebe; Javier Cuesta; Evald Høj Christiansen; Salvatore Cassese; Petra Hoppmann; Roisin Colleran; Fiona Harzer; Jola Bresha; Nejva Nano; Simon Schneider; Karl-Ludwig Laugwitz; Michael Joner; Adnan Kastrati; Robert A Byrne
Journal:  Int J Cardiovasc Imaging       Date:  2021-08-21       Impact factor: 2.357

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.